With nearly 20 percent of U.S. adults affected by depression, the prevalence of this mental health condition drives many to explore relief from its most challenging symptoms. A recent study offers ...

The FDA on Thursday approved a transcranial direct current stimulation (tDCS) device as the first at-home non-drug therapy for major depression in adults, maker Flow Neuroscience announced.

The FDA has approved Flow, a prescription home-use cranial electrotherapy stimulation device, for treating moderate to severe ...

In a first, the US FDA has approved a device that allows you to treat depression at home. The headset delivers a mild electric current to the part of the brain that is known to regulate mood ...

While most tDCS devices have limitations in precise stimulation and show varying treatment effectiveness due to not considering individual brain structures, Neurophet has developed an AI-powered ...

Depression affects approximately 280 million people all over the world, and disproportionately affects the female population — it is 50% more common in women than men. Treatments range from ...

BOSTON, March 11, 2025 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, and Sooma Medical, a world-leading provider of ...

When added to stable selective serotonin reuptake inhibitors (SSRI) treatment, transcranial direct current stimulation (tDCS) was not superior to sham stimulation for major depressive disorder (MDD), ...

A noninvasive, home-based brain treatment with transcranial direct current stimulation (tDCS) can reduce pain severity, improve pain-related disability, and enhance endogenous pain modulation in women ...